L-ASPARAGINASE

L-Asparaginase is an enzyme-based anticancer agent used primarily in treating acute lymphoblastic leukaemia (ALL), a rapidly progressive blood cancer. The drug functions by depleting asparagine, an amino acid required for proliferation of certain malignant cells. Originally isolated from the bacterium Escherichia coli, L-Asparaginase gained FDA approval in 1978. Subsequently, multiple formulations have been introduced, including pegylated and Erwinia-derived variants, to minimise hypersensitivity reactions. Clinical trials have established efficacy during the induction and consolidation phases of paediatric and adult leukaemia treatment protocols. When incorporated into combination chemotherapy regimens, it has substantially enhanced survival rates, particularly in children with ALL.

L-asparaginase is used for: Treatment of acute lymphoblastic leukaemia (ALL) Treatment of lymphoblastic lymphoma (a subtype of non-Hodgkin lymphoma) Part of the combination chemotherapy regimens in pediatric and adult ALL patients

L-Asparaginase is given either through a vein (IV) or into a muscle (IM), depending on the type of the drug and the patient’s condition. Some versions, like the pegylated form, stay in the body longer and don’t need to be given as often. The dose is calculated based on the patient's body size and may change during different stages of treatment, such as the beginning, middle, or end. It comes in different forms, including ones made from E. coli , pegylated versions, and others made from Erwinia chrysanthemi .

Serious side effects: Pancreatitis Thrombosis or bleeding Hepatic dysfunction Allergic reactions or anaphylaxis Hyperglycemia Central nervous system effects (confusion, somnolence, seizures) Common side effects: Nausea and vomiting Fatigue Fever Joint or muscle pain Decreased appetite Mild rash Abdominal discomfort

Severe hypersensitivity reactions, including anaphylaxis, may occur, especially with repeated administration. Pancreatitis is a potentially life-threatening complication and warrants immediate drug discontinuation. Coagulopathy and thrombosis : The drug may alter coagulation factors, increasing the risk of bleeding or clotting events. Hepatotoxicity : Elevated liver enzymes and liver dysfunction have been reported. Neurotoxicity : Can cause confusion, lethargy, or even seizures in rare cases. Drug interactions : Caution when combined with other hepatotoxic or nephrotoxic drugs.

Patients receiving this therapy should undergo routine monitoring of liver enzymes, pancreatic function, coagulation parameters, and complete blood counts. It is critical to ensure no prior history of hypersensitivity to the same formulation. Any sign of abdominal pain, bleeding, or altered mental status should be evaluated promptly. In patients with pre-existing liver or pancreatic conditions, the use of this drug should be carefully assessed. Healthcare providers should be trained in managing infusion-related reactions and emergency interventions.

Complete all prescribed cycles of treatment as directed, even if symptoms improve early, as stopping treatment may result in disease relapse. Avoid alcohol and hepatotoxic substances during therapy. Maintain adequate hydration, attend all scheduled follow-up appointments, and report any side effects without delay. Because of the risk of immune reactions, each dose must be administered in a medical facility with capacity to manage emergencies. Medical identification should be worn during long-term therapy with this medication.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/aspamer080102LB.pdf https://www.cancer.gov/news-events/cancer-currents-blog/2021/fda-rylaze-asparaginase-childhood-leukemia https://www.cancer.gov/publications/dictionaries/cancer-drug/def/asparaginase https://www.cancer.gov/about-cancer/treatment/drugs/asparaginase-erwinia-chrysanthemi